HT
BTAI icon

Headlands Technologies’s BioXcel Therapeutics BTAI Stock Holding History

Headlands Technologies’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36K Buy
+25,556
New +$29.9K ﹤0.01% 684

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Headlands Technologies's BTAI Position: Q2 2026 in Review

Headlands Technologies opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 25,556 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #684 among its holdings.

46 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Headlands Technologies held 25,556 shares of BioXcel Therapeutics worth $36K as of Q2 2026.
  • BioXcel Therapeutics was a new Headlands Technologies position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Headlands Technologies's portfolio in Q2 2026, its #684 holding.
  • 46 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.